Medindia

X

CardioGenics Spotlighted in May Issue of Medical Tourism Magazine

Friday, May 28, 2010 General News J E 4
Advertisement
CEO Yahia Gawad Discusses Advances in Rapid Point-of-Care Testing and How They Could Benefit Patients Traveling Abroad for Cardiac Procedures

MISSISSAUGA, Ontario, May 28 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, is spotlighted in the May issue of Medical Tourism Magazine in an article written by CardioGenics founder and CEO Yahia Gawad, MD.

In the article, titled "The In Vitro Diagnostics Market and the Fight Against Heart Problems," Dr. Gawad notes that reducing the time required to diagnose a cardiac event is a key factor in saving the lives of patients with acute heart problems.  Recent significant growth in the IVD market promises a new generation of technological advances -- such as CardioGenics' QL Care Analyzer -- that will improve options for rapid Point-of-Care (POC) testing abroad as well as in the U.S.

"A significant fraction of patients who travel overseas for surgery are doing so because of heart problems," Dr. Gawad writes in the article.  "In fact, heart surgery is one of the top five types of surgeries that motivate travel abroad.  But this fact begs the question:  What happens if one experiences an acute cardiac episode overseas before one has had the chance to undergo one's scheduled procedure?  The fact is that the amount of time it takes to diagnose a heart attack is currently much longer in foreign countries in comparison to North America."  

Dr Gawad goes on to write that new technology is being developed that may finally level this particular playing field.  Specifically, he highlights the rapid growth in the POC test market, encompassing diagnostic tests that can be conducted at or near the site of patient care.  A Troponin I (TNI) test, a Plasminogen Activator Inhibitor type-1 (PAI-1) test, a heart failure risk stratification test, and a heart failure genomics risk test are all in development for the benefit of cardiac care patients.

"If and when POC immunoanalyzers are sold abroad...the effect on medical tourism will likely be significant," writes Gawad in the article.  "No longer will heart patients need to fret about lack of timely diagnosis when suffering a possible cardiac episode prior to undergoing their scheduled procedure in a foreign healthcare facility.... The time required for accurate diagnosis will be rapidly reduced and roughly equalized everywhere."

To read the entire article online, please visit http://www.medicaltourismmag.com/detail.php?Req=366&issue=17.

About Medical Tourism Magazine

Medical Tourism Magazine is published by the Medical Tourism Association™, the first international non-profit association made up of the top international hospitals, healthcare providers, medical travel facilitators, insurance companies, and other affiliated companies and members with the common goal of promoting the highest level of quality of healthcare to patients in a global environment. The association promotes the interests of its healthcare provider and medical tourism facilitators members. The Medical Tourism Association ™ has three tenets: Transparency, Communication and Education. For more information, please visit www.medicaltourismmag.com.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops its Point-Of-Care analyzer and products targeting the immunoassay segment of the IVD market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating magnetic beads (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement -Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VaxGen to Acquire diaDexus in a Stock-for-Stock Me...
S
Authentidate Receives Notice from Nasdaq Regarding...